TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05141305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenecteplase (0.25 mg/kg, Max 25 mg)
Description: tenecteplase (0.25 mg/kg) is being used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medical treatment
Description: Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.
Study: NCT06548867

Intervention type: DRUG
Intervention: Cabozantinib
Description: Patients must have been treated with cabozantinib after one or more previous therapies for mRCC, as per clinical practise.

Intervention type: DRUG
Intervention: Cabozantinib
Description: Patients must have been treated with cabozantinib after one or more previous therapies for mRCC, as per clinical practise.
Study: NCT05400148

Intervention type: DRUG
Intervention: Bupivacaine Hydrochloride
Description: Patients who were administered an analgesic PENG block with a dose of 2.5mg/kg with either lov (\<20ml) or high volume (\>20ml)

Intervention type: DRUG
Intervention: Bupivacaine Hydrochloride
Description: Patients who were administered an analgesic PENG block with a dose of 2.5mg/kg with either lov (\<20ml) or high volume (\>20ml)
Study: NCT05870904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry Needling includes the insertion of a fine, strong filiform needle without presentation of any pain relieving medicine.~Ischemic pressure is usually applied to trigger point, in what is known as trigger point therapy, where enough continuous pressure is applied to a trigger point within a tolerable measure of pain, and as discomfort is decreased, extra pressure is gradually applied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Dry Needling includes the insertion of a fine, strong filiform needle without presentation of any pain relieving medicine.~Ischemic pressure is usually applied to trigger point, in what is known as trigger point therapy, where enough continuous pressure is applied to a trigger point within a tolerable measure of pain, and as discomfort is decreased, extra pressure is gradually applied
Study: NCT04944108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISA approach
Description: Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter) or the INSURE approach (tracheal tube)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insure approach
Description: Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
Study: NCT06075225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is asministrated with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days.
Study: NCT06014944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
Description: neoadjuvant therapy for short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody for PMMR / MSS type middle and low locally advanced rectal cancer.
Study: NCT05273684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Participants will undergo 4x4 and 1x10 minutes of interval training on two separate days.
Study: NCT04870437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal phototherapy
Description: The principle of ECP is to collect mononucleated cells from the blood by centrifugation. After purification, the mononucleated cells are incubated ex-vivo with a photo-activatable DNA intercalating agent (8-methoxypsoralen, UVADEX®), then re-injected to the patient.
Study: NCT06355570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Pictures
Description: Digital photos will be shown continuously at the patient's bedside for 12 hours a day (between 8 am to 8 pm).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Videos
Description: Family-recorded videos will be played three times at specific hours of the day - 9 am, 2 pm and 7 pm - throughout patient stay in the ICU

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Videos - Intervention as required
Description: The last video shown will be re-played upon patient request and/or if patients develop ICU delirium.
Study: NCT06310746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GARP/TGF-β1 monoclonal antibody
Description: It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg).
Study: NCT04550130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TLA Gut™
Description: The medical device to be investigated is named Tailored Leukapheresis (TLA) Gut™. The device comprises a column that has been designed for extracorporeal leukapheresis to specifically remove chemokine (C-C motif) receptor 9 (CCR9) expressing immunological cell populations including human leukocyte antigen DR isotype (HLA-DRhi ) monocytes from the circulation. This is achieved by integrating a strong affinity binding between the gut homing cell receptor, CCR9, and its cognate ligand, thymus-expressed chemokine (TECK) or chemokine ligand 25 (CCL25). Those blood cells that express CCR9 will bind to presented Biotinylated thymus-engineered chemokine (bTECK) on the matrix by a strong receptor ligand interaction, remaining bound to the matrix. Blood cells that do not express the receptor pass through the column unchanged and are returned to the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TLA Gut™
Description: The medical device to be investigated is named Tailored Leukapheresis (TLA) Gut™. The device comprises a column that has been designed for extracorporeal leukapheresis to specifically remove chemokine (C-C motif) receptor 9 (CCR9) expressing immunological cell populations including human leukocyte antigen DR isotype (HLA-DRhi ) monocytes from the circulation. This is achieved by integrating a strong affinity binding between the gut homing cell receptor, CCR9, and its cognate ligand, thymus-expressed chemokine (TECK) or chemokine ligand 25 (CCL25). Those blood cells that express CCR9 will bind to presented Biotinylated thymus-engineered chemokine (bTECK) on the matrix by a strong receptor ligand interaction, remaining bound to the matrix. Blood cells that do not express the receptor pass through the column unchanged and are returned to the patient.
Study: NCT06427460

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Central-boost ablative dose delivered by stereotactic body radiation therapy
Description: An inner and complete gross tumor volume (iGTV) is created within the gross tumor volume (GTV). For the liver or lung tumor, the convetional radiation dose is 35-45Gy/5f. Regarding the pancreatic tumor or retroperitoneal tumor, the radiation dose is 30-40Gy/5f. Hence, the radiation dose of iGTV should not be less than 120% of the dose of GTV.
Study: NCT05683483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WEsleep Interventions
Description: 1) Postponing morning nursing rounds to avoid waking patients early and daily assessment of sleep quality by the nurse during morning rounds; 2) Implementing sleep promoting interventions, including optimization of medication and iv fluid timing; 3) Education for health care professionals on sleep; 4) Implementing sleep rounds and change department infrastructure; including 'sleep menu' where patients can choose from earplugs, eye masks, and warm socks. Implement blackout curtains depending on baseline light intensity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WEsleep Interventions
Description: 1) Postponing morning nursing rounds to avoid waking patients early and daily assessment of sleep quality by the nurse during morning rounds; 2) Implementing sleep promoting interventions, including optimization of medication and iv fluid timing; 3) Education for health care professionals on sleep; 4) Implementing sleep rounds and change department infrastructure; including 'sleep menu' where patients can choose from earplugs, eye masks, and warm socks. Implement blackout curtains depending on baseline light intensity.
Study: NCT05542238

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One bout of moderate-intensity sub-maximal aerobic exercise
Description: The intervention is a 20-min acute exercise using arm ergometer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One bout of moderate-intensity sub-maximal aerobic exercise
Description: The intervention is a 20-min acute exercise using arm ergometer
Study: NCT06342869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: application of different anesthesia techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: application of different anesthesia techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: application of different anesthesia techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: application of different anesthesia techniques
Study: NCT06237517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of Vasomotion of People With Idiopathic Chilblains
Description: Investigation of vasomotion of people with and without idiopathic chilblains

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of Vasomotion of People With Idiopathic Chilblains
Description: Investigation of vasomotion of people with and without idiopathic chilblains

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of Vasomotion of People With Idiopathic Chilblains
Description: Investigation of vasomotion of people with and without idiopathic chilblains
Study: NCT05216081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)
Description: Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
Study: NCT06237517

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of Vasomotion of People With Idiopathic Chilblains
Description: Investigation of vasomotion of people with and without idiopathic chilblains

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of Vasomotion of People With Idiopathic Chilblains
Description: Investigation of vasomotion of people with and without idiopathic chilblains

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of Vasomotion of People With Idiopathic Chilblains
Description: Investigation of vasomotion of people with and without idiopathic chilblains
Study: NCT06332898

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG1 - Nutritional Supplement
Description: A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin placebo
Study: NCT05671380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Longitudinal Proactive Outreach (LPO).
Description: All participants will receive personalized invitation materials (in their preferred language) with messages culturally and linguistically tailored to BIPOC communities, guided by the literature on culturally adapting evidence-based interventions. The study team will tailor these resources in collaboration with the CE core. The tailored mailed packet will include an invitation letter and a brochure describing the types of tobacco treatment services available from their health system and from Quit Partner. One week after the written materials are sent, participants assigned to this condition will receive LPO by a MI-trained coach. The MI outreach call protocol will consist of 6 contact attempts over two weeks.The MI outreach call protocol will be repeated at 3, 6, and 9 months for a total of four outreach cycles because participants may not have quit or may have relapsed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask-Advice-Connect (AAC)
Description: Licensed Practical Nurses will be trained to ask all patients if they smoke, document smoking status in the EHR, advise patients to stop smoking, and complete an electronic referral to Quit Partner or the smoking cessation clinic. AAC will be designed to connect participants to Quit Partner Minnesota to receive tobacco cessation counseling. Quit Partner™ is a family of programs available to help Minnesota residents quit commercial tobacco, administered by the Minnesota Department of Health (MDH). Quit Partner programs are provided by National Jewish Health (NJH). Any Minnesota resident can access a free 2-week supply of Nicotine Replacement Therapy (NRT). Uninsured and underinsured residents can access the full Quit Partner programs, including free one-on- one coaching, more NRT, and additional supports. Quit Partner also offers four population- specific programs and calls are available in several languages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ask-Advice-Connect (AAC)
Description: Licensed Practical Nurses will be trained to ask all patients if they smoke, document smoking status in the EHR, advise patients to stop smoking, and complete an electronic referral to Quit Partner or the smoking cessation clinic. AAC will be designed to connect participants to Quit Partner Minnesota to receive tobacco cessation counseling. Quit Partner™ is a family of programs available to help Minnesota residents quit commercial tobacco, administered by the Minnesota Department of Health (MDH). Quit Partner programs are provided by National Jewish Health (NJH). Any Minnesota resident can access a free 2-week supply of Nicotine Replacement Therapy (NRT). Uninsured and underinsured residents can access the full Quit Partner programs, including free one-on- one coaching, more NRT, and additional supports. Quit Partner also offers four population- specific programs and calls are available in several languages.
Study: NCT06221982

Intervention type: OTHER
Intervention: No intervention, observational study
Description: Observational study, no intervention
Study: NCT05310214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Treatment with ACP will be performed by inserting sterile acupuncture needles 0.25 x 13 mm into the acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji , for the treatment of chronic non-specific low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~In order to increase the effectiveness of blinding for both groups, in this study the model was adopted: combined simulated control. In this case, Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. Thus, in the ACP group, the placebo LACP (without dosemetry) will be applied to these 4 points together with the real treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laser acupuncture
Description: The use of LACP (808 nm wavelength, 100 mW, energy 6 J per acp point), on acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji will be used as a treatment for nonspecific chronic low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. These sham points will be inserted superficially so that the depth is sufficient to keep them fixed during the experiment, without individuals reporting the dequi.
Study: NCT05468021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Randomized Clinical Trial (study design) to evaluate the effectiveness of an educational intervention to increase vaccine uptake among socioeconomically disadvantaged adults. The intervention will consist of a health promoter with an educational toolkit addressing misinformation, distrust, and hesitancy regarding the COVID-19 vaccine. An educational website with videos addressing COVID-19 vaccine will be available to study participants to boost information provided in the educational toolkit.
Study: NCT05275205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX1325 injection 50 μL
Description: Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28
Study: NCT02238457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose losartan
Description: 25 mg losartan bid for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose losartan
Description: 50 mg, 75 mg, or 100 mg bid for 10 weeks. Dose will be determined by the medical doctor depending on patients' tolerability
Study: NCT04809610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet attachment-based compassion therapy (iABCT).
Description: The iABCT is a self-applied program based on the attachment theory and the use of compassion meditations. It is composed of 8 modules that have been reformulated to be completely self-applied and include text, images, illustrations, videos, audio with guided meditations, exercises and homework. Downloadable PDF files will be made available so that users can review them offline. Each module has been optimized to have a duration of 60 and 90 minutes approximately. The entire intervention is estimated to be completed in eight weeks.
Study: NCT05581732

Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutrinidrink with Dietary Fiber
Description: Nutrinidrink with Dietary Fiber is a specialized nutrition for children during illness and recovery period, as well as with increased protein and energy needs: mental and / or physical stress, chronic diseases, growth and / or weight deficiency
Study: NCT06092294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactical training in numerical superiority and numerical inferiority
Description: In the present study, the SSGs training sessions will be carried out in the following areas:~2c1: length 11.5m and width 9m (total: 103.5m2), equivalent to 34.5m2 for each player.~3c2: length 14m and width 12m (total: 168m2), equivalent to 33.6m2 for each player.~4c3: length 17m and width 14m (total: 238m2), equivalent to 34m2 per each player.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training in numerical equality
Description: Coach who will run the CG training program will be different from the coach who will run the GE training program. As with the GE, a coach will also be assigned to the CG to record, quantify and monitor the training stimuli of this comparison group, who will record it on forms designed for this purpose.
Study: NCT05275205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Description: Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28.
Study: NCT06522776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: The investigator adapted the manual of psychological intervention based on Cognitive Behavioral Therapy (CBT) which previously was validated in patients with chronic kidney disease. Patients received CBT using a model of six modules, with a time of 60 minutes for each weekly session. For each module, a skill acquisition criterion was used, to know if the participants were putting the techniques into practice in their daily lives and to know if it was pertinent to move on to the next module. Modules were adapted to the needs of each participant. In consequence, the number of sessions was different for each patient. All participants had a follow-up session one month after they finished the psychological therapy. Additionally, a daily self-record of symptoms perception and a short questionnaire on the usefulness of each technique used were sent daily to the participants via a phone text message.
Study: NCT06040294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DDS program
Description: dementia virtual reality and disability simulation of activity design for seniors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dementia course with no DDS
Description: Regular dementia course and group discussions of activity design for seniors with no DDS
Study: NCT04553211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPT
Description: Expedited Partner Therapy (EPT) involves provision of empiric oral antibiotic therapy to the recent sexual partners of an individual diagnosed with gonorrhea and/or chlamydia infection.
Study: NCT05748379

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Kompozite closure
Description: Immediate implant placement and temporary closure of tapered implants with a custom-made composite shaper.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Individual abutment
Description: Immediate implant placement and temporary closure of tapered implant with a custom-made zirconium oxide abutment.
Study: NCT06193941

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-qPCR
Description: RT-qPCR

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-qPCR
Description: RT-qPCR

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-qPCR
Description: RT-qPCR
Study: NCT05348798

Intervention type: OTHER
Intervention: Web based survey
Description: Web-based survey on exercise addiction and personality traits
Study: NCT06017154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor-Cognitive Training Program
Description: The training will incorporate cognitive tasks which focus on reaction time, processing speed, working memory, cognitive flexibility, and inhibitory control using visual stimuli on a screen or through sensors which illuminate using LED lights. These cognitive tasks will be performed while also executing physical performance tasks that challenge static and dynamic postural stability, lateral movement, agility, and other movement patterns. The training session will last approximately 30 minutes and participants will complete up to 5 exercises
Study: NCT05645471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Together After Cancer
Description: This is an online couples intervention for Latina breast cancer survivors and their intimate partners.